Log in to your Inderes Free account to see all free content on this page.
Oncopeptides
3.61 SEK
-16.92 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-16.92 %
-24.87 %
-27.80 %
-30.17 %
+10.84 %
+177.92 %
-56.64 %
-96.67 %
-87.50 %
Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.
Read moreMarket cap
984.47M SEK
Turnover
39.06M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19.2.
2026
Annual report '25
13.5.
2026
Interim report Q1'26
21.5.
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Oncopeptides announces Q4 2025 sales and updates cash-flow expectations
Research shows that Pepaxti is effective in high-risk myeloma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
